Discussing next-gen AAV vectors with Dr Arun Srivastava, University of Florida
Posted: 30 September 2021 | Drug Target Review | No comments yet
An interview with Dr Arun Srivastava about his research into safe and effective AAV vectors that do not prompt a reaction from the immune system.
Sign up for Drug Target Review‘s Cell & Gene Therapy Advancements Online Summit for FREE here
Dr Arun Srivastava, Professor at the University of Florida, speaks with Drug Target Review‘s Deputy Editor Victoria Rees about his research into AAV vectors and their use in gene therapy. He explains why they can prompt an immune response from hosts when administered: “Any time you inject a foreign protein into the body, it will mount an immune response… so what is amazing about this virus is that it is fairly mildly immunogenic. The problem has been that lately, biotech companies have been injecting massive doses of this vector into patients and beyond a certain limit, the immune system simply gives out.”
Dr Srivastava outlines his research to combat this, delving into how next-generation AAV vectors can be developed to deliver gene therapies more safely and effectively to patients. He explores his most promising findings and how close these are to reaching patients.
To hear Dr Srivastava expand on his research and listen to other experts in the world of gene therapies discuss AAV vectors, sign up for Drug Target Review‘s Cell & Gene Therapy Advancements Online Summit for FREE here: https://bit.ly/3a3tjfo
Related topics
Biologics, Biopharmaceuticals, Drug Delivery, Gene Therapy, In Vitro, In Vivo, Therapeutics, Translational Science
Related people
Dr Arun Srivastava (University of Florida)